OCT guided vs. COmplete pci in patieNts with sT segment elevation myocArdial infarCtion and mulTivessel disease: OCT-CONTACT RCT

医学 传统PCI 心脏病学 经皮冠状动脉介入治疗 心肌梗塞 内科学 狼牙棒 罪魁祸首 部分流量储备 随机对照试验 血运重建 临床终点 冠状动脉造影
作者
Mario Iannaccone,Ovidio De Filippo,Andrea Montabone,Giorgio Marengo,Ludovica Maltese,Fabrizio Ugo,Giorgio Quadri,Maro MENNUNI,Gioel Gabrio Secco,Vittorio Taglialatela,Sebastian Cinconze,Claudio Moretti,Alessandra Truffa,Alfonso Gambino,Giacomo Boccuzzi,Vincenzo Infantino,Federico Conrotto,Alessandro Lupi,Ferdinando Varbella,Giuseppe Patti
出处
期刊:Minerva cardiology and angiology [Edizioni Minerva Medica]
卷期号:71 (4) 被引量:4
标识
DOI:10.23736/s2724-5683.22.06144-0
摘要

In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significantly reduces the risk of cardiovascular death. However, the management of non-culprit lesions in patients with the multivessel disease remains a matter of debate in this setting. It's still unclear if a morphological OCT-guided approach, identifying coronary plaque instability, may provide a more specific treatment compared with a standard angiographic/functional approach.OCT-Contact is a prospective, multicenter, open-label, non-inferiority randomized controlled trial. Patients with STEMI with successful primary PCI of the culprit lesion will be enrolled after the index PCI. Patients will be deemed eligible if a critical coronary lesion other than the culprit (associated with a diameter of stenosis ≥50%) will be identified during the index angiography. Patients will be randomized in a 1:1 fashion to OCT-guided PCI of non-culprit lesions (Group A) vs. complete PCI (Group B). PCI in group A will be undertaken according to criteria of plaque vulnerability, while in group B the use of fractional flow reserve will be left at the operators' discretion. Major-adverse cardiovascular events (MACE) are a composite of all-cause mortality, non-fatal myocardial infarction (MI) (excluding peri-procedural MI), unplanned revascularization, and NYHA IV heart failure) will be the primary efficacy outcome. Single components of MACE along with cardiovascular mortality will be the secondary endpoints. . Safety endpoints will embrace worsening of renal failure, procedural complications, and bleedings. Patients will be followed for 24 months after randomization.A sample size of 406 patients (203 per group) is required to provide the analysis an 80% power to detect a non-inferiority in the primary endpoint with an alpha error set at 0.05 and a non-inferiority limit of 4%.A morphological OCT-guided approach may be a more specific treatment compared with the standard angiographic/functional approach in non-culprit lesions of STEMI patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
现代的画笔完成签到,获得积分10
3秒前
铜豌豆完成签到 ,获得积分10
4秒前
小白一枚完成签到 ,获得积分10
5秒前
惜昭发布了新的文献求助10
7秒前
纯真怜梦完成签到,获得积分20
7秒前
奋斗的妙海完成签到 ,获得积分0
17秒前
wzhang完成签到,获得积分10
18秒前
20秒前
20秒前
20秒前
a水爱科研完成签到,获得积分10
20秒前
cheng4046完成签到,获得积分10
25秒前
25秒前
27秒前
烦烦发布了新的文献求助10
29秒前
30秒前
andy应助科研通管家采纳,获得10
31秒前
33秒前
康康完成签到 ,获得积分10
33秒前
xxz完成签到,获得积分10
34秒前
英姑应助烦烦采纳,获得10
40秒前
碧蓝的紫寒完成签到,获得积分10
43秒前
xyj完成签到,获得积分10
44秒前
49秒前
悲凉的问芙完成签到,获得积分20
50秒前
w0r1d完成签到 ,获得积分10
51秒前
shilly完成签到 ,获得积分10
52秒前
文艺的熠彤完成签到,获得积分10
53秒前
行云岛发布了新的文献求助10
54秒前
大胆的夏天完成签到,获得积分10
55秒前
Hello应助霉盘采纳,获得10
57秒前
碧蓝的紫寒关注了科研通微信公众号
58秒前
田小甜完成签到 ,获得积分10
1分钟前
迅速的仰完成签到 ,获得积分10
1分钟前
拼搏的白云完成签到,获得积分10
1分钟前
科研通AI6.3应助小蓝采纳,获得10
1分钟前
从容谷菱完成签到 ,获得积分10
1分钟前
灰太狼完成签到,获得积分10
1分钟前
行云岛完成签到,获得积分20
1分钟前
香蕉觅云应助wuqs采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
Various Faces of Animal Metaphor in English and Polish 800
Signals, Systems, and Signal Processing 610
Photodetectors: From Ultraviolet to Infrared 500
On the Dragon Seas, a sailor's adventures in the far east 500
Yangtze Reminiscences. Some Notes And Recollections Of Service With The China Navigation Company Ltd., 1925-1939 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6353185
求助须知:如何正确求助?哪些是违规求助? 8168047
关于积分的说明 17191458
捐赠科研通 5409215
什么是DOI,文献DOI怎么找? 2863646
邀请新用户注册赠送积分活动 1840978
关于科研通互助平台的介绍 1689834